CytomX Therapeutics is a biotechnology company focused on developing innovative cancer therapies through its proprietary Probody™ therapeutic technology
This platform is designed to selectively activate antibody-based treatments in the tumor microenvironment, helping to enhance the efficacy and reduce potential side effects of cancer therapies. CytomX is engaged in creating a pipeline of product candidates aiming to address various types of cancer, leveraging its expertise in protein engineering and immuno-oncology to advance treatment options and improve patient outcomes. The company collaborates with pharmaceutical partners to accelerate the development of its therapeutic candidates, with the goal of bringing novel, targeted therapies to market.
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
